Samson SL, Nachtigall LB, Fleseriu M, et al. - In this Phase 3 CHIASMA OPTIMAL trial, researchers tested the safety and effectiveness of oral octreotide capsules (OOC) in patients with acromegaly who previously showed biochemical control while receiving injectable somatostatin receptor ligands (SRLs). For this double-blind study, individuals (N = 56) stratified by prior SRL dose were randomized 1:1 to OOC or placebo for 36 weeks. At baseline and end of treatment, mean IGF-I were 0.80 and 0.97 x ULN for OOC and 0.84 and 1.69 x ULN for placebo.  It was noted that mean GH changed from 0.66 to 0.60 ng/mL for OOC and 0.90 to 2.57 ng/mL for placebo. OOC can be an effective therapy for patients with acromegaly who have previously been treated with injectable SRLs.